Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
8-KCurrent report12/20/202112/17/2021
8-KCurrent report11/23/202111/23/2021
8-K/ACurrent report - amendment11/16/202111/10/2021
4Statement of changes in beneficial ownership of securities11/15/202111/15/2021
10-QQuarterly report [Sections 13 or 15(d)]11/10/20219/30/2021
8-KCurrent report11/10/202111/10/2021
3Initial statement of beneficial ownership of securities11/9/202111/2/2021
8-KCurrent report11/3/202111/3/2021
DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material10/28/2021
DEF 14AOther definitive proxy statements10/28/202112/17/2021
DNotice of Exempt Offering of Securities10/28/2021
8-KCurrent report10/28/202110/27/2021
4Statement of changes in beneficial ownership of securities10/19/202110/18/2021
4Statement of changes in beneficial ownership of securities10/19/202110/18/2021
4Statement of changes in beneficial ownership of securities10/19/202110/18/2021
4Statement of changes in beneficial ownership of securities10/19/202110/18/2021
4Statement of changes in beneficial ownership of securities10/19/202110/18/2021
S-8Securities to be offered to employees in employee benefit plans10/18/2021
8-KCurrent report10/13/202110/13/2021
8-KCurrent report10/1/202110/1/2021
8-KCurrent report9/30/20219/30/2021
4Statement of changes in beneficial ownership of securities9/30/20219/29/2021
4Statement of changes in beneficial ownership of securities9/29/20219/28/2021
4Statement of changes in beneficial ownership of securities9/29/20219/28/2021
8-KCurrent report9/24/20219/24/2021
10-KAnnual report [Section 13 and 15(d), not S-K Item 405]9/24/20216/30/2021
8-KCurrent report9/20/20219/17/2021
8-KCurrent report9/13/20219/10/2021
8-KCurrent report9/10/20219/9/2021
8-KCurrent report9/8/20219/7/2021
  • « Previous
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*